Literature DB >> 21693371

How to calculate left ventricular mass in routine practice? An echocardiographic versus cardiac magnetic resonance study.

Ludivine Perdrix1, Nicolas Mansencal, Benjamin Cocheteux, Gilles Chatellier, Alvine Bissery, Benoit Diebold, Elie Mousseaux, Eric Abergel.   

Abstract

BACKGROUND: An accurate assessment of left ventricular (LV) mass is important for the detection of LV hypertrophy. AIMS: To assess the accuracy of four echocardiographic imaging modalities for assessing LV mass compared with cardiac magnetic resonance (CMR).
METHODS: We prospectively studied 40 consecutive patients, who underwent an echocardiographic examination using four imaging modalities (M-mode fundamental imaging [FI], M-mode harmonic imaging [HI], two-dimensional [2D] FI and 2D HI) and CMR (our gold standard for LV mass measurement). All echocardiographic measurements were performed by two independent observers.
RESULTS: All echocardiographic modes significantly overestimated LV mass compared with CMR (P≤0.04), except 2D FI (P=0.25). This overestimation was significantly higher with HI (up to 15.5%) compared with FI (up to 5.7%; P≤0.04). Significant correlations were observed between the different echocardiographic methods and the two observers. The interobserver agreement over LV mass measurement was lower with FI (intraclass coefficient [ICC] range, 0.66-0.73) than with HI (ICC range, 0.72-0.82), and the best agreement was obtained with 2D HI (ICC, 0.82). Good agreement between CMR and all echocardiographic methods was observed among the smallest LV diameters (ICC range, 0.62-0.85), but not among the largest LV diameters (ICC range, 0-0.22).
CONCLUSIONS: HI overestimates LV mass compared with FI and CMR; this leads to overestimation of prevalence of LV hypertrophy in a population of hypertensive patients. HI improves interobserver reproducibility of LV mass measurement compared with FI, leading to a significant decrease in the number of patients required for clinical trials evaluating LV mass regression. Accuracy of LV mass measurement by echocardiography is affected by LV geometry.
Copyright © 2011. Published by Elsevier Masson SAS.

Entities:  

Mesh:

Year:  2011        PMID: 21693371     DOI: 10.1016/j.acvd.2011.04.003

Source DB:  PubMed          Journal:  Arch Cardiovasc Dis        ISSN: 1875-2128            Impact factor:   2.340


  10 in total

1.  Left ventricular mass and systolic function in children with chronic kidney disease-comparing echocardiography with cardiac magnetic resonance imaging.

Authors:  Raoul Arnold; Daniel Schwendinger; Sabine Jung; Martin Pohl; Bernd Jung; Julia Geiger; Charlotte Gimpel
Journal:  Pediatr Nephrol       Date:  2015-09-05       Impact factor: 3.714

2.  Relationship between left ventricular mass and coronary artery disease in young adults: a single-center study using cardiac computed tomography.

Authors:  Jae Yong Cho; Joo Sung Sun; Young Keun Sur; Jin Sun Park; Doo Kyoung Kang
Journal:  Int J Cardiovasc Imaging       Date:  2015-10-01       Impact factor: 2.357

Review 3.  LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice.

Authors:  Anderson C Armstrong; Samuel Gidding; Ola Gjesdal; Colin Wu; David A Bluemke; João A C Lima
Journal:  JACC Cardiovasc Imaging       Date:  2012-08

4.  Two-dimensional speckle tracking echocardiography demonstrates no effect of active acromegaly on left ventricular strain.

Authors:  I C M Volschan; L Kasuki; C M S Silva; M L Alcantara; R M Saraiva; S S Xavier; M R Gadelha
Journal:  Pituitary       Date:  2017-06       Impact factor: 4.107

5.  Left ventricular relative wall thickness versus left ventricular mass index in non-cardioembolic stroke patients.

Authors:  M-Sherif Hashem; Hayrapet Kalashyan; Jonathan Choy; Soon K Chiew; Abdel-Hakim Shawki; Ahmed H Dawood; Harald Becher
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

Review 6.  The emerging role of Cardiovascular Magnetic Resonance in the evaluation of hypertensive heart disease.

Authors:  Sophie Mavrogeni; Vasiliki Katsi; Vasiliki Vartela; Michel Noutsias; George Markousis-Mavrogenis; Genovefa Kolovou; Athanasios Manolis
Journal:  BMC Cardiovasc Disord       Date:  2017-05-23       Impact factor: 2.298

Review 7.  Cardiac Imaging in Heart Failure with Comorbidities.

Authors:  Chiew Wong; Sylvia Chen; Pupalan Iyngkaran
Journal:  Curr Cardiol Rev       Date:  2017

8.  The influence of LV geometry on the occurrence of abnormal exercise tests in athletes.

Authors:  Danny A J P van de Sande; Jan Hoogsteen; Pieter A Doevendans; Hareld M C Kemps
Journal:  BMC Cardiovasc Disord       Date:  2019-01-06       Impact factor: 2.298

9.  Green tea halts progression of cardiac transthyretin amyloidosis: an observational report.

Authors:  Arnt V Kristen; Stephanie Lehrke; Sebastian Buss; Derliz Mereles; Henning Steen; Philipp Ehlermann; Stefan Hardt; Evangelos Giannitsis; Rupert Schreiner; Uwe Haberkorn; Philipp A Schnabel; Reinhold P Linke; Christoph Röcken; Erich E Wanker; Thomas J Dengler; Klaus Altland; Hugo A Katus
Journal:  Clin Res Cardiol       Date:  2012-05-15       Impact factor: 5.460

10.  Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study.

Authors:  Fabian aus dem Siepen; Ralf Bauer; Matthias Aurich; Sebastian J Buss; Henning Steen; Klaus Altland; Hugo A Katus; Arnt V Kristen
Journal:  Drug Des Devel Ther       Date:  2015-12-04       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.